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group with AO; and between AO groups within overweight sub-
group overall and within genders. RESULTS: Baseline analysis
was conducted in overweight/obese subjects (BMI > or =
25kg/m2) with AO (n = 674, male 42%, female 58%, mean age
50, 91% Caucasian) and without AO (n = 293, male 73%,
female 27%, mean age 50, 88% Caucasian). Overall, subjects
with AO reported a statistically signiﬁcantly (p < 0.05) lower
total score and lower scores in all 5 domains compared with sub-
jects without AO. In subjects with AO, women had statistically
signiﬁcant lower scores, for all domains and total score, com-
pared with men (p < 0.05). Overweight subjects (BMI 25–30
kg/m2) with AO (n = 220) also reported a statistically signiﬁ-
cantly (p < 0.05) lower total score compared with overweight
subjects without AO (n = 254), in the overall population, as well
as in women. In men, the only difference observed was in the
Physical Function score. CONCLUSION: AO was associated
with impaired HRQOL (assessed using the IWQOL-Lite) for
both men and women, with decreases for women being more
marked. The data obtained in this Internet-based cohort are con-
sistent with those from the literature.
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OBJECTIVES: To evaluate the impact of the ﬁrst selective
cannabinoid type 1 (CB1) receptor blocker, rimonabant, devel-
oped for the management of cardiometabolic risk factors, on
health related quality of life (HRQOL). METHODS: Over 6600
overweight/obese patients, with or without comorbidities were
randomized in double-blind, placebo-controlled, 2 ﬁxed doses (5
mg and 20mg), parallel-group clinical trials. Patients completed
the Impact of Weight on Quality of Life-Lite (IWQOL-Lite) and
the Short-Form Health Survey (SF-36) questionnaires at baseline
and every 3 months up to 1 year. The IWQOL-Lite is a validated
31-item self-reported questionnaire speciﬁcally designed for
HRQOL assessment in obesity and comprises 5 domains and a
total score. SF-36 is a standardized generic HRQOL measure
used in general population (non-speciﬁc for obesity). Analyses
presented were performed on mean score changes from baseline
to 1 year in the intent-to-treat population. RESULTS: At 1 year,
patients administered rimonabant 20mg once daily reported
consistently greater improvement in IWQOL-Lite scores than
patients in the placebo group in all domains (Physical Function,
Self-esteem, Sexual Life, Public Distress, Work) and total score
(p < 0.001, except Work, p = 0.03). SF-36 provided statistically
signiﬁcant results for 5/8 domains (p < or = 0.05); 3 of them
(Physical Functioning, Bodily Pain, General Health) supported
greater improvement with rimonabant, while the other 2 (Role
Emotional and Mental Health) were less decreased with placebo.
Overall, HRQOL results appeared to be less clinically meaning-
ful on the SF-36 [effect sizes (ES) ranging between 0.01 and 0.33,
depending on the score considered] than on the IWQOL-Lite (ES
between 0.22 and 0.45). CONCLUSION: Using an obesity-
speciﬁc questionnaire (IWQOL-Lite), rimonabant 20mg was
associated with a signiﬁcant and sustained improvement in
HRQOL up to 1 year. As expected, SF-36 appeared to be less
sensitive to clinical changes in this overweight/obese population.
RESPIRATORY DISEASES—Clinical Outcomes Studies
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OBJECTIVES: Recent studies have suggested that use of inhaled
corticosteroids (ICS) may improve survival in COPD, particularly
when combined with a long-acting beta agonist (LABA).
However, the methods used to conduct these retrospective studies
have been questioned and none have examined what effect the
newer combination ICS/LABA inhalers may have on survival. The
goal of this project was to further examine the relationship
between ICS treatment, with or without LABA, and survival in
COPD. METHODS: COPD patients were identiﬁed from the
administrative databases of four different managed care pro-
grams: Lovelace Health Plan (Albuquerque NM), Health Part-
ners Health System (Minneapolis/St Paul MN), Henry Ford
Health System’s Alliance Plan (Detroit MI), and Harvard Pilgrim
Health Care (Boston MA). All patients who were diagnosed with
COPD between September 1, 2000 and August 31, 2001 and who
had at least 3 months treatment with either ﬂuticasone/salmeterol
(ADVAIR, N = 866), some other ICS/LABA (N = 525), ICS alone
(N = 742), LABA alone (N = 531), or a short-acting bron-
chodilator alone (SABD, N = 1832), were included. RESULTS:
In the basic Cox proportional hazards models, use of ADVAIR,
ICS/LABA, and ICS alone had signiﬁcant survival beneﬁts as com-
pared to SABD alone, after adjustment for differences in age,
gender, comorbidities, asthma status, and disease severity (HRs
0.638, 0.603, and 0.784, respectively, p < 0.05). Propensity score
matching to reduce the clinical differences between the treatment
groups versus the SABD reference groups found very similar
results. Nested case-control matching based on survival status
continued to show a highly signiﬁcant survival beneﬁt for
ADVAIR; other treatments also had favorable RR that did not
reach statistical signiﬁcance. CONCLUSIONS: Treatment with
ADVAIR or another ICS with or without LABA is associated with
improved survival in COPD. The treatment beneﬁt seen with
ADVAIR is robust to a number of analyses designed to adjust for
differences in clinical parameters and bias by indication.
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OBJECTIVES: Bronchodilators, including anticholinergics, are
central to the management of COPD. Current guidelines recom-
mend the use of bronchodilators in the management of mild to
moderate COPD and inhaled corticosteroids for severe patients
and patients with repeated exacerbations. This analysis evaluates
COPD patients treated with an inhaled corticosteroid or an anti-
cholinergic to determine the difference in treatment patterns and
costs between the two groups. METHODS: In a retrospective
database study, continuously enrolled patients aged 18 years and
older with a COPD diagnosis (COPD only or COPD+asthma),
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who initiated therapy during year 2002 with either an inhaled
corticosteroid or an anticholinergic (ﬁrst ﬁll date identiﬁed as
index date) were included in the analyses. Patients were followed
for one year prior to and one year after the index date. Rate of
switching and augmentation between the two groups was ana-
lyzed descriptively. Multivariate analyses controlling for patient
demographics, comorbidities, baseline health resource utilization
and physician specialty were used to compare costs between the
two groups. RESULTS: Of the 8392 patients identiﬁed as having
COPD, 467 (5.56%) initiated an inhaled corticosteroid and 495
(5.90%) initiated an anticholinergic. Rate of switching (12% 
vs. 10%) and augmentation (32% vs. 24%) was higher in the
inhaled corticosteroid group as compared to the anticholinergic
group. After adjusting for the confounding factors, multivariate
analysis revealed that the initiating inhaled corticosteroid group
had 68% higher respiratory costs and 20% higher overall costs
as compared to the initiating anticholinergic group during the
one-year follow-up period (p < 0.05). CONCLUSIONS: The
inhaled corticosteroid users had higher rates of switching/aug-
mentation and higher respiratory and overall costs as compared
to the anticholinergic users. Future research determining the
reasons for higher follow-up cost in the inhaled corticosteroid
group would be helpful.
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OBJECTIVES: The Canadian Thoracic Society (CTS) guidelines
for the management of Chronic Obstructive Pulmonary Disease
(COPD) recommend incorporating combination therapy [long-
acting B2-agonist (LABA) and an inhaled-corticosteroid (ICS)]
for select COPD patients but have not evaluated the associated
economic implications. Our objective was to provide economic
information to inform decision makers whether to recommend
combination therapy to none, all, or a select group of COPD
patients. METHODS: Using clinical guidelines and current man-
agement of COPD as the basis for the analysis, a markov model
was constructed to determine, from a health systems perspective,
the cost-effectiveness of combination therapy versus LABA alone
between four treatment strategies: 1) maintenance therapy for all
patients using LABA alone (base case); and in addition to the
base case, 2) provide combination therapy for severe cases
(forced expiratory volume in 1 second [FEV1] < 35% predicted);
3) provide combination therapy for moderate or severe cases
(FEV1 < 50% predicted); and 4) provide combination therapy
for all COPD patients. Estimates of mortality, exacerbation and
disease progression rates, and outcomes (QALY) were derived
from a systematic review of the literature. Cost estimates were
based on current Alberta healthcare costs. A time horizon of 3
years was used. RESULTS: Beginning with the lowest cost inter-
vention of LABA for all cases: the incremental cost-effectiveness
ratio (ICER) of providing combination therapy for severe
patients was $9670 per QALY gained. The marginal ICER for
providing combination therapy for moderate and severe cases 
is $31,606 per QALY gained and providing combination therapy
for all stages of disease was $271,241 per QALY gained. 
CONCLUSION: It would be cost-effective to provide combina-
tion therapy for moderate and severe COPD patients. This analy-
sis has signiﬁcant implications for the planned revision of CTS
guidelines because it promotes the wider use of combination
therapy in COPD populations with greater severity.
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OBJECTIVES: COPD is a leading cause of morbidity and mor-
tality in the U.S., and is a major source of healthcare costs. Life-
time costs of COPD and its impact on life expectancy have 
not been adequately quantiﬁed. METHODS: We developed a
Markov model to project mortality and costs from COPD over
an individual’s remaining lifetime. The model proﬁles patients
with diagnosed COPD by sex, age (30, 40, 50, 60, 70, 80 years),
smoking status (current, former, never smoker), and COPD
severity (GOLD stages I–IV). Changes/transitions for these
factors, along with mortality, occur in each one-year model cycle.
Data were obtained from published sources and analyses of gov-
ernment survey and claims databases. The model projects direct
costs (undiscounted and discounted to 2005 US$ at 3% per
annum) and life expectancy (age at death and quality-adjusted
life years [QALYs] remaining). RESULTS: For a “typical” COPD
patient (60 years old, former smoker, GOLD stage I or II), dis-
counted lifetime costs of COPD were projected to range from
$38,000–$74,000 (men) and $43,000–$85,000 (women) for
GOLD stages I and II, respectively. Unadjusted remaining life
expectancy was 19.6/22.0 years (men/women) for GOLD stage
I, and 16.6/19.0 years (men/women) for GOLD stage II.
Men/women in GOLD stages I and II respectively had 1.4/2.3
and 4.4/5.3 fewer years remaining in life compared to average
60-year-olds in the general U.S. population. Quality-adjusted life
expectancy for men/women was 17.0/18.9 and 12.0/13.7 QALYs
for GOLD stages I and II, respectively. CONCLUSION: Lifetime
burden of COPD for individuals with the disease is considerable.
Costs and life-years lost for GOLD stage II patients are about
double to triple for those in GOLD stage I. These results high-
light the potential clinical and economic beneﬁts of slowing
disease progression.
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Little is known about the costs of treating idiopathic pulmonary
ﬁbrosis (IFP), an infrequent but often fatal chronic respiratory
disease. OBJECTIVE: To assess resource use and costs of care
for IPF, pulmonary care, and all healthcare services among newly
diagnosed IPF patients. METHODS: Patients newly diagnosed
with IPF were identiﬁed from the administrative claims records
of a large state Medicaid program. Patients were selected for
inclusion if they had (1) 1+ inpatient claims or 2+ outpatient
claims listing a ICD-9-CM diagnosis of IPF (515, 516.3¥)
between July 1999-June 2003; and (2) fee-for-service, Medicaid-
only coverage for 12+ months before and after their ﬁrst
observed claim with an IPF diagnosis (“index date”). Patients
who died during the 12-month post-index period also were
included. Patients were excluded if they had an IPF diagnosis 
in the 12 months prior to the index date, or diagnoses for 
extrinsic allergic alveolitis, pneumoconioses, lung diseases due to
